Woodline Partners LP Mannkind Corp Transaction History

Woodline Partners LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$3.72 - $4.79 $5.03 Million - $6.48 Million	-1,352,154 Reduced 73.72%	482,126 $1.96 Million
Q1 2023 May 15, 2023	BUY	$3.95 - $5.63 $4.4 Million - $6.27 Million	1,113,420 Added 154.46%	1,834,280 $7.52 Million
Q4 2022 Feb 14, 2023	SELL	$3.02 - $5.37 $3.41 Million - $6.06 Million	-1,128,529 Reduced 61.02%	720,860 $3.8 Million
Q3 2022 Nov 14, 2022	BUY	$2.99 - $4.35 $5.53 Million - $8.04 Million	1,849,389 New	1,849,389 $5.72 Million
Q2 2022 Aug 15, 2022	SELL	$2.67 - $4.77 $632,565 - $1.13 Million	-236,916 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$2.62 - $4.45 $620,719 - $1.05 Million	236,916 New	236,916 $872,000
Q4 2021 Feb 14, 2022	SELL	$4.05 - $5.37 $1.17 Million - $1.55 Million	-288,655 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$3.89 - $5.48 $1.12 Million - $1.58 Million	288,655 New	288,655 $1.26 Million

243

148M

1.62M

802K

Ticker MNKD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 257,338,000
Market Cap $1.57B
Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.